OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
O
OneMedNetOneMedNet provides a platform for curating and exchanging real-world medical imaging and clinical data from healthcare provider networks to power life sciences, AI development, and academic research.
2 Pulse stories
Total Raised
$430M
Ollin BiosciencesOneMedNet
Last ValuationNot disclosed
Biotech
Sector
Biotech
2023
Founded
2006
Chicago, Illinois
HQ
Eden Prairie, Minnesota
Private
Status
Public (ONMD)
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
OneMedNet investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Ollin Biosciences and OneMedNet.